Related Experiment Video
Updated: May 29, 2025
Polymeric Microneedle Array Fabrication by Photolithography
Published on: November 17, 2015
A Spatially Distributed Microneedle System for Bioorthogonal T Cell-Guided Cancer Therapy
Lanya Li1,2, Fei Wang1, Shushan Mo3
1The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, China.
Abstract:
Chimeric antigen receptor (CAR)-T cell therapy represents a promising strategy for cancer treatment. However, the diversity of solid tumor antigens and the poor infiltration of CAR-T cells significantly hinder the efficacy of CAR-T therapies against tumors. Here, a spatially distributed microneedle system (SDMNS) is developed that leverages bioorthogonal reactions to activate and guide endogenous T cells to tumors for effective destruction. The SDMNS consists of two dissolving microneedles, each loaded with complementary bioorthogonal groups and applied separately to lymph nodes and tumor sites. One microneedle loaded with two dibenzocyclooctyne (DBCO)-modified antibodies activates T cells and labels them with bioorthogonal groups in lymph nodes. The other microneedle, containing N-azidoacetylmannosamine-tetraacylated (Ac4ManNAz) for glycometabolic labeling of tumor cells, and the T cell chemotactic factor IP10, is applied directly to the tumor site. The in vivo studies demonstrate that SDMNS effectively directs the migration and infiltration of endogenous activated T cells into the tumors. Through a bioorthogonal click reaction, DBCO-modified T cells conjugate with azide (N3)-modified tumor cells, eliciting robust antitumor immune responses and durable immune memory. The SDMNS offers a novel strategy to overcomes tumor heterogeneity by facilitating the directed migration of endogenous T cells.
Insights
This study introduces a microneedle system to activate and guide the body's own T cells to solid tumors. This approach enhances T cell infiltration and destruction of cancer cells, overcoming limitations of current therapies.
Area of Science:
- Immunology
- Biotechnology
- Materials Science
Background:
- Chimeric antigen receptor (CAR)-T cell therapy shows promise for cancer treatment but faces challenges with solid tumor antigen diversity and poor T cell infiltration.
- Existing CAR-T cell therapies are hindered by the heterogeneity of solid tumors and insufficient T cell penetration.
Purpose of the Study:
- To develop a spatially distributed microneedle system (SDMNS) that utilizes bioorthogonal reactions to activate and guide endogenous T cells towards tumors for enhanced cancer destruction.
- To overcome limitations in CAR-T cell therapy efficacy against solid tumors by leveraging the body's own immune cells.
Main Methods:
- A dual microneedle system was designed, with one needle applied to lymph nodes to activate and label T cells with bioorthogonal groups (DBCO-modified antibodies).
- The second microneedle, applied to the tumor site, contained reagents for tumor cell labeling (Ac4ManNAz) and a T cell chemoattractant (IP10).
- Bioorthogonal click chemistry was employed for T cell-tumor cell conjugation following T cell migration and infiltration.
Main Results:
- In vivo studies confirmed that the SDMNS effectively directed the migration and infiltration of endogenous activated T cells into tumor sites.
- The system successfully facilitated a bioorthogonal click reaction between DBCO-modified T cells and azide-modified tumor cells.
- This interaction triggered potent antitumor immune responses and established durable immune memory.
Conclusions:
- The developed spatially distributed microneedle system (SDMNS) offers a novel strategy to enhance T cell-mediated antitumor immunity.
- SDMNS effectively directs endogenous T cells to tumors, overcoming challenges posed by tumor heterogeneity and poor infiltration.
- This approach represents a promising advancement for cancer immunotherapy by leveraging bioorthogonal chemistry and T cell guidance.
